EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Metabotropic glutamate receptors and drug addiction

Richard M. Cleva, M. Foster Olive

Wiley Interdisciplinary Reviews: Membrane Transport and Signaling · 2012

DOI: 10.1002/wmts.18 ↗
AbstractBibliografische Angaben

Abstract

Abstract Historically, brain catecholamine systems have been the primary focus of studies examining the neural substrates of drug addiction. In the past two decades, however, a wealth of evidence has accumulated indicating a pivotal role for glutamatergic neurotransmission in mediating addictive behaviors as well as long‐term neuroplasticity associated with chronic drug use. As a result, there has been increased interest in developing glutamate‐based therapies for the treatment of addictive disorders. Metabotropic glutamate (mGlu) receptors are classified into subcategories designated as Group I (mGlu1 and mGlu5), Group II (mGlu2 and mGlu3), and Group III (mGlu4, mGlu6, mGlu7, and mGlu8) and have received a great deal of attention due to their mediation of slower modulatory excitatory neurotransmission. Pharmacological ligands targeting these receptors have demonstrated reduced incidences of excitotoxicity or severe adverse side effects as compared to those targeting ionotropic glutamate (iGlu) receptors. Behavioral genetic and pharmacological studies have explored the role of individual mGlu receptor subtypes in regulating various addiction‐related behaviors, and several mGlu receptor ligands have been the subject of clinical testing for other medical conditions. WIREs Membr Transp Signal 2012,1:281–295. doi: 10.1002/wmts.18 For further resources related to this article, please visit the WIREs website .

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →